Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Blood

• Publication date

  2016-03-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2015-12-684399PMID 26825707PMCID PMC4817310
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cytokine profiles in Mycoplasma pneumoniae infection-associated hemophagocytic lymphohistiocytosis.

  2016cited by this paper
• Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis

  2015cited by this paper
• Mechanisms of Jak/STAT Signaling in Immunity and Disease

  2015cited by this paper
• JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms

  2015cited by this paper
• Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders.

  2015cited by this paper
• JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms.

  2015cited by this paper
• Hemophagocytic syndromes--an update.

  2014cited by this paper
• Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

  2013cited by this paper
• Hemophagocytic lymphohistiocytosis in syntaxin-11-deficient mice: T-cell exhaustion limits fatal disease.

  2013cited by this paper
• Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8(+) T cells and dendritic cells.

  2013cited by this paper
• The adaptor molecule SAP plays essential roles during invariant NKT cell cytotoxicity and lytic synapse formation.

  2013cited by this paper
• Cytokine profiles in children with primary Epstein–Barr virus infection

  2013cited by this paper
• Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model.

  2013cited by this paper
• Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

  2013cited by this paper
• The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.

  2013cited by this paper
• Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab

  2013cited by this paper
• Ruxolitinib: A New Treatment Option for Myelofibrosis

  2013cited by this paper
• Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?

  2013cited by this paper
• Gene-expression signatures differ between different clinical forms of familial hemophagocytic lymphohistiocytosis.

  2013cited by this paper
• Familial and acquired hemophagocytic lymphohistiocytosis.

  2012cited by this paper
• Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

  2012cited by this paper
• Biology and significance of the JAK/STAT signalling pathways

  2012cited by this paper
• A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

  2012cited by this paper
• Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes.

  2012cited by this paper
• Protection from Inflammatory Organ Damage in a Murine Model of Hemophagocytic Lymphohistiocytosis Using Treatment with IL-18 Binding Protein

  2012cited by this paper
• Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib

  2012cited by this paper
• Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.

  2012cited by this paper
• JAK Kinases in Health and Disease: An Update

  2012cited by this paper
• Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis

  2012cited by this paper
• Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.

  2012cited by this paper
• Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.

  2012cited by this paper
• Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice.

  2011influential reference
• Perforin is a critical physiologic regulator of T-cell activation.

  2011cited by this paper
• Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol.

  2011cited by this paper
• The regulation of IL-10 production by immune cells

  2010cited by this paper
• Cytokine Profiles of Macrophage Activation Syndrome Associated with Rheumatic Diseases

  2010cited by this paper
• Neutralization of IFNγ defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice

  2009cited by this paper
• Familial and acquired hemophagocytic lymphohistiocytosis

  2006influential reference
• Perforin and granzymes have distinct roles in defensive immunity and immunopathology.

  2006cited by this paper
• An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder.

  2004cited by this paper
• Interleukin-18 in Hemophagocytic Lymphohistiocytosis

  2001cited by this paper
• Hypercytokinemia in familial hemophagocytic lymphohistiocytosis.

  1991cited by this paper

• Sequential JAK inhibition enhances antitumor immunity after combined anti–PD-1 and anti-CTLA4

  2025cites this paper
• Salvage treatment of AOSD-associated macrophage activation syndrome with bariticinib following conventional immunosuppressive therapy

  2025cites this paper
• PRMT5 inhibition reduces hyperinflammation in a murine model of secondary hemophagocytic lymphohistiocytosis

  2025cites this paper
• Weathering the HLH storm and redesigning clinical trials.

  2025cites this paper
• Retrospective analysis of ruxolitinib as induction treatment in pediatric hemophagocytic lymphohistiocytosis

  2025cites this paper
• Latest updates on pathogenesis mechanisms and management strategies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis related to CAR-T cell therapies

  2025cites this paper
• Griscelli Syndrome Type 2 Revealed by Macrophage Activation Syndrome: Two Cases From the Same Family

  2025cites this paper
• Ruxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndrome

  2025cites this paper
• Ruxolitinib Is an Effective Therapy for Ciltacabtagene Autoleucel-Associated Parkinsonism in Multiple Myeloma

  2025cites this paper
• Promising Targeted Therapies for Hemophagocytic Lymphohistiocytosis: A Translational Perspective Based on Immunopathology

  2025cites this paper
• Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China.

  2025cites this paper
• Breaking the cycle: PRMTs and secondary HLH relief

  2025cites this paper
• Histiocyte Society blueprint for hemophagocytic lymphohistiocytosis research: deciphering underlying disease mechanisms to optimize diagnosis and therapy

  2025cites this paper
• Hemophagocytic Lymphohistiocytosis in the Context of Hematological Malignancies and Solid Tumors.

  2024cites this paper
• 改良MINE方案治疗侵袭性NK细胞白血病和T细胞淋巴瘤继发噬血细胞综合征3例并文献复习

  2024cites this paper
• Ruxolitinib attenuates microglial inflammatory response by inhibiting NF-κB/MAPK signaling pathway.

  2024cites this paper
• Murine Models of Familial Cytokine Storm Syndromes.

  2024cites this paper
• Cytokine Storm Syndrome Associated with Systemic Juvenile Idiopathic Arthritis.

  2024cites this paper
• Ruxolitinib-based senomorphic therapy mitigates cardiomyocyte senescence in septic cardiomyopathy by inhibiting the JAK2/STAT3 signaling pathway

  2024cites this paper
• Murine Models of Secondary Cytokine Storm Syndromes.

  2024cites this paper
• Monocytic Phagocytes in the Immunopathogenesis of Cytokine Storm Syndromes.

  2024cites this paper
• Progress in Diagnosis and Treatment of Lymphoma-Associated Hemophagocytic Syndrome

  2024cites this paper
• Editorial: Towards a better understanding of hemophagocytic lymphohistiocytosis

  2024cites this paper
• Treatment of secondary hemophagocytic syndrome

  2024cites this paper
• CD8+ T Cell Biology in Cytokine Storm Syndromes.

  2024cites this paper
• Hemophagocytic lymphohistiocytosis post chimeric antigen receptor T cell therapies

  2024cites this paper
• The History of Macrophage Activation Syndrome in Autoimmune Diseases.

  2024cites this paper
• Ruxolitinib as a salvage therapy in adult-onset macrophage activation syndrome: insights from eight cases

  2024cites this paper
• Heterogeneity of macrophage activation syndrome and treatment progression

  2024cites this paper
• History of Hemophagocytic Lymphohistiocytosis.

  2024cites this paper
• Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms

  2024cites this paper
• A Novel Engineering Cell Therapy Platform Mimicking the Immune Thrombocytopenia‐Derived Platelets to Inhibit Cytokine Storm in Hemophagocytic Lymphohistiocytosis

  2024cites this paper
• Differential Effects of JAK1 vs. JAK2 Inhibition in Mouse Models of Hemophagocytic Lymphohistiocytosis.

  2024cites this paper
• Hemophagocytic lymphohistiocytosis caused by multiple infections during primary chemotherapy for pediatric acute lymphoblastic leukemia: a case report

  2024cites this paper
• Case report: Infection-associated HPS during pregnancy cured by HLH-94 protocol with induction therapy of ruxolitinib

  2024cites this paper
• IL-6 Blockade in Cytokine Storm Syndromes.

  2024cites this paper
• Salvage Therapy and Allogeneic Hematopoietic Cell Transplantation for the Severe Cytokine Storm Syndrome of Hemophagocytic Lymphohistiocytosis.

  2024cites this paper
• Phage Display as a Medium for Target Therapy Based Drug Discovery, Review and Update

  2024cites this paper
• Ruxolitinib‐based regimen in children with autoimmune disease or autoinflammatory disease‐related haemophagocytic lymphohistiocytosis

  2024influential citation
• JAK Inhibitors in Cytokine Storm Syndromes.

  2024cites this paper
• The Role of the IL-33/ST2 Axis in CpG-Induced Macrophage Activation Syndrome

  2023cites this paper
• Sử dụng Ruxolitinib trong điều trị hội chứng thực bào máu ở trẻ em tại bệnh viện Nhi Đồng 2

  2023cites this paper
• An analysis of sintilimab combined with ruxolitinib as compassionate therapy for 12 adults with EBV-associated hemophagocytic lymphohistiocytosis

  2023cites this paper
• Case report: Ruxolitinib plus dexamethasone as first-line therapy in haemophagocytic lymphohistiocytosis

  2023cites this paper
• Ruxolitinib-based regimen in children with primary hemophagocytic lymphohistiocytosis

  2023cites this paper
• Typical hemophagocytic syndrome associated with cytomegalovirus infection in an immunocompetent patient: a case report and literature review

  2023cites this paper
• Early B cell development and B cell maturation are impaired in patients with active hemophagocytic lymphohistiocytosis.

  2023cites this paper
• Biological therapies for hemophagocytic lymphohistiocytosis: current knowledge and future perspectives

  2023cites this paper
• Secondary hemophagocytic lymphohistiocytosis in children (Review)

  2023cites this paper
• Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis

  2023cites this paper
• An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor

  2023cites this paper
• Successful treatment of hemophagocytic lymphohistiocytosis in a patient with systemic lupus erythematosus with ruxolitinib: a case report

  2023cites this paper
• Urgenţe în reumatologia pediatrică (I) – sindromul de activare macrofagică

  2023cites this paper
• Efficacy of combined low-dose ruxolitinib and cyclosporine in murine immune bone marrow failure

  2023cites this paper
• The Liver in Hemophagocytic Lymphohistiocytosis: Not an Innocent Bystander

  2023cites this paper
• Cellular and transcriptional impacts of Janus kinase and/or IFN-gamma inhibition in a mouse model of primary hemophagocytic lymphohistiocytosis

  2023cites this paper
• JAK inhibitors in systemic juvenile idiopathic arthritis

  2023cites this paper
• A case of hemophagocytic lymphohistiocytosis with a significant response to baricitinib: a first report with review of literature

  2023cites this paper
• The Multifaceted Immunology of Cytokine Storm Syndrome.

  2023cites this paper
• Case report: Durable response to ruxolitinib in a child with TREX1-related disorder

  2023cites this paper
• Emerging aspects of cytokine storm in COVID-19: the role of proinflammatory cytokines and therapeutic prospects

  2023cites this paper
• CXCL9 inhibition does not ameliorate disease in murine models of both primary and secondary hemophagocytic lymphohistiocytosis

  2023cites this paper
• Hemophagocytic lymphohistiocytosis: A disorder of T cell activation, immune regulation, and distinctive immunopathology

  2023cites this paper
• Ruxolitinib as an Effective Treatment for Hemophagocytic Lymphohistiocytosis Secondary to SARS-Cov-2 Infection: A Case Report

  2023cites this paper
• Recent advances in the treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome

  2022cites this paper
• Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH)

  2022cites this paper
• Cytokine nanosponges suppressing overactive macrophages and dampening systematic cytokine storm for the treatment of hemophagocytic lymphohistiocytosis

  2022influential citation
• Novel Biosensor Identifies Ruxolitinib as a Potent and Cardioprotective CaMKII Inhibitor

  2022cites this paper
• Adult-Onset Still’s Disease—A Complex Disease, a Challenging Treatment

  2022cites this paper
• Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS

  2022cites this paper
• HLH treatment: smarter, not harder.

  2022cites this paper
• Practice patterns and outcomes of hemophagocytic lymphohistiocytosis in adults: a 2-decade provincial retrospective review

  2022cites this paper
• The clinical heterogeneity of adult onset Still's disease may underlie different pathogenic mechanisms. Implications for a personalised therapeutic management of these patients.

  2022cites this paper
• Ruxolitinib for Refractory Macrophage Activation Syndrome Complicating Adult-Onset Still’s Disease

  2022cites this paper
• Development and application of an LC-MS/MS method for pharmacokinetic study of ruxolitinib in children with hemophagocytic lymphohistiocytosis.

  2022cites this paper
• Combined IFNγ and JAK inhibition to treat hemophagocytic lymphohistiocytosis in mice.

  2022cites this paper
• Ruxolitinib as Adjunctive Therapy for Hemophagocytic LymPhohistiocytosis after Liver Transplantation: A Case Report and Literature Review

  2022cites this paper
• Treatment Strategies for Central Nervous System Effects in Primary and Secondary Haemophagocytic Lymphohistiocytosis in Children

  2022cites this paper
• A study of Ruxolitinib-response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis.

  2022cites this paper
• Ruxolitinib attenuates secondary injury after traumatic spinal cord injury

  2022influential citation
• Above the Regular Tide: Primary Immune Regulatory Disorders (PIRD) Diagnosis and Treatment Considerations

  2022cites this paper
• Transient Inhibition of the JAK/STAT Pathway Prevents B-ALL Development in Genetically Predisposed Mice

  2022cites this paper
• Progress in Biological Therapies for Adult-Onset Still’s Disease

  2022influential citation
• [Ruxolitinib as an effective treatment for panniculitis associated hemophagocytic syndrome: A report of 2 cases and literature review].

  2022cites this paper
• Hemophagocytic lymphohistocytosis in trisomy 21: successful treatment with interferon inhibition

  2022cites this paper
• Lung Involvement in Systemic Juvenile Idiopathic Arthritis: A Narrative Review

  2022cites this paper
• BTT_A_290329 21..34

  2022influential citation
• Population pharmacokinetics of ruxolitinib in children with hemophagocytic lymphohistiocytosis: focus on the drug–drug interactions

  2022cites this paper
• The Treatment Based on Ruxolitinib and Amphotericin B is Effective for Relapsed Leishmaniasis-Related Hemophagocytic Lymphohistiocytosis: A Case Report and Literature Review

  2022influential citation
• Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis

  2021cites this paper
• COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon

  2021cites this paper
• Ruxolitinib in conjunction with the HLH-94 protocol for Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in the intensive care unit

  2021cites this paper
• The Pathogenic Role of Interferons in the Hyperinflammatory Response on Adult-Onset Still’s Disease and Macrophage Activation Syndrome: Paving the Way towards New Therapeutic Targets

  2021cites this paper
• Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome

  2021influential citation
• Successful management of familial hemophagocytic lymphohistiocytosis by the JAK 1/2 inhibitor ruxolitinib

  2021cites this paper
• Clinical features, diagnosis and therapy of familial haemophagocytic lymphohistiocytosis

  2021cites this paper
• Ruxolitinib‐combined doxorubicin‐etoposide‐methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single‐arm, multicentre, phase 2 trial

  2021cites this paper
• Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis

  2021cites this paper
• Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib

  2021cites this paper
• Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?

  2021cites this paper